Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16127
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Villemagne, Victor L | - |
dc.contributor.author | Rowe, Christopher C | - |
dc.contributor.author | Okamura, Nobuyuki | - |
dc.date.accessioned | 2016-08-15T06:08:07Z | - |
dc.date.available | 2016-08-15T06:08:07Z | - |
dc.date.issued | 2016-06-04 | - |
dc.identifier.citation | Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2016; 4: 39-42 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/16127 | - |
dc.description.abstract | In vivo imaging of tau deposits is providing a better understanding of the temporal and spatial tau deposition in the brain, allowing a more comprehensive insight into the causes, diagnoses, and potentially treatment of tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. The assessment of tau deposition in the brain over time will allow a deeper understanding of the relationship between tau and other variables such as cognition, genotype, and neurodegeneration, as well as assessing the role tau plays in ageing. Preliminary human studies suggest that tau imaging could also be used as a diagnostic, prognostic, and theranostic biomarker, as well as a surrogate marker for target engagement, patient recruitment, and efficacy monitoring for disease-specific therapeutic trials. | en |
dc.subject | PET | en |
dc.subject | Tau imaging | en |
dc.subject | Alzheimer's disease | en |
dc.subject | Positron emission tomography | en |
dc.subject | Tauopathies | en |
dc.subject | Dementia | en |
dc.title | Untangling tau imaging | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | en |
dc.identifier.affiliation | Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Molecular Imaging and Therapy | en |
dc.identifier.affiliation | The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Department of Medicine, The University of Melbourne, Parkville, Australia | en |
dc.identifier.affiliation | Department of Pharmacology, Tohoku University, Sendai, Japan | en |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/27489878 | en |
dc.identifier.doi | 10.1016/j.dadm.2016.05.001 | en |
dc.type.content | Text | en |
dc.identifier.orcid | 0000-0003-3910-2453 | en |
dc.type.austin | Journal Article | en_US |
local.name.researcher | Rowe, Christopher C | |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.